Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?

Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be consider...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Duflot, Ly Tu, Matthieu Leuillier, Hind Messaoudi, Déborah Groussard, Guillaume Feugray, Saïda Azhar, Raphaël Thuillet, Fabrice Bauer, Marc Humbert, Vincent Richard, Christophe Guignabert, Jérémy Bellien
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lysophospholipids lysophosphatidic acids cardiovascular diseases HPLC-MS/MS rodent models pulmonary hypertension Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/2813d9874b6f4b77aef908b7dc9296a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?

Ejemplares similares